APP and Alzheimer disease: SIRT1 levels are brain region-dependent in AD [49], being able to degrade the Aβ peptide in primary astrocytes and to reduce ROS and peroxidation levels in APP/PS1 AD model, decreasing senile plaques and improving learning and memory activities [52–54].